Objectives: Phenotypic and genotypic methods for the detection of antimicrobial resistance (AMR) in enteroaggregative Escherichia coli (EAEC) were compared and evaluated.
Introduction
Enteroaggregative Escherichia coli (EAEC) were first identified as a cause of gastrointestinal (GI) infections in 1987 and were originally characterized by their ability to adhere to HEp-2 cells in a stacked-brick pattern. 1 More recently, 'typical' EAEC have been defined as EAEC that harbour the key virulence factor AggR, a member of the AraC/XyIS family of bacterial transcription regulators. 2 The aggR gene is located on the aggregative adherence plasmid and controls a number of genes encoding virulence factors located on both the plasmid and the chromosome. 2 Studies have shown that EAEC are a heterogeneous group of strains of E. coli with respect to their evolutionary origins, plasmid content and presence or absence of additional virulence factors, such as the Aai pathogenicity island, serine protease autotransporters and other toxins. [3] [4] [5] EAEC cause acute or persistent watery diarrhoea (with or without mucus) in children, predominantly in low-income countries 6 and are associated with travellers' diarrhoea in children and adults in middle-and high-income countries. 7 Other symptoms include nausea and vomiting, anorexia, borborygmi and tenesmus. 8 In low-income countries the propensity of EAEC to cause persistent diarrhoea for .2 weeks is associated with significant morbidity. Although symptoms may persist for weeks, infection is usually self-limiting and the standard recommended treatment is oral rehydration therapy. However, the symptoms can be debilitating and have a high socio-economic impact, particularly in lowincome settings, and treatment may be sought if the diarrhoea and abdominal pain is severe and/or prolonged.
Global studies have highlighted a high incidence of antimicrobial resistance (AMR) in strains of E. coli belonging to the EAEC pathotype in comparison with other E. coli pathotypes. [9] [10] [11] [12] [13] The aim of this study was to compare phenotypic AMR profiles with those derived from WGS data in EAEC isolated from cases of diarrhoeal disease in England between 2015 and 2016.
Methods

Bacterial isolates
The Gastrointestinal Bacteria Reference Unit (GBRU) at PHE receives faecal specimens from hospital laboratories in England when local PCR assays detect the presence of a GI bacterial pathogen but no causative organism can be identified by culture. All EAEC (n " 155) isolated by GBRU between July 2015 and December 2016 were included in this study. The isolates were from 155 patients presenting to general practitioners or local hospitals with GI symptoms.
WGS
Genomic DNA was extracted, fragmented and tagged for multiplexing with Nextera XT DNA Sample Preparation Kits, followed by paired-end sequencing on an Illumina HiSeq platform to produce 80-100 bp short-read sequence fragments (Illumina, Cambridge, UK). The ST and serotype were determined from the genome data, as previously described.
14 AMR determinants were sought using 'Genefinder', a customized algorithm that uses Bowtie 2 to map reads to a set of reference sequences and Samtools to generate an mpileup file. 15 The latter was than parsed line by line to determine the base calls at each nucleotide position with filtering based on read depth (.5 reads per base) and base call agreement (.85%). The presence of genes was defined based on 100% read coverage and .90% nucleotide identity relative to the reference sequence 13, 16 with the exception of b-lactamase variants, which were determined with 100% identity using the reference sequences downloaded from the Lahey (www. lahey.org) and NCBI (https://www.ncbi.nlm.nih.gov/pathogens/beta-lacta mase-data-resources) b-lactamase data resources.
Known acquired resistance genes and resistance-conferring mutations relevant to b-lactams (including carbapenems), fluoroquinolones, aminoglycosides, chloramphenicol, macrolides, sulphonamides, tetracyclines, trimethoprim, rifamycins, colistin and fosfomycin were included in the analysis. Reference sequences for acquired resistance genes were curated from those described in the Comprehensive Antimicrobial Resistance Database 1.1.4 (http://arpcard.mcmaster.ca) and the ResFinder 17-Feb-2017 datasets (https://cge.cbs.dtu.dk/services/data.php) by removing duplicate sequences that were identified by Blast. Chromosomal mutations focused on variations in the QRDRs of gyrA, gyrB, parC and parE, which are associated with resistance to quinolones, and in rpoB for rifampicin resistance.
To investigate genotype-phenotype discrepancies, reads were assembled de novo with VelvetOptimiser-2.1.9 (http://www.vicbioinfor matics.com/software.velvetoptimiser.shtml). Contigs carrying genes of interest were identified by Blast and manually inspected. The MLST ST assignment was performed using the MOST software (https://github.com/ phe-bioinformatics/MOST). 17 FASTQ sequences were deposited in the National Center for Biotechnology Information Short Read Archive under the BioProject PRJNA315192. Accession numbers for each sequence are listed in Table S1 (available as Supplementary data at JAC Online).
Antimicrobial susceptibility testing
Susceptibility testing was performed retrospectively on all isolates recovered from the GBRU archive. MICs for 155 isolates were determined by agar dilution using Mueller-Hinton agar for the following antimicrobials: ampicillin, nalidixic acid, ciprofloxacin, streptomycin, gentamycin, trimethoprim, tetracycline, sulphonamides, chloramphenicol, rifampicin, fosfomycin and azithromycin. Breakpoints used for interpretation were as recommended by EUCAST and the EU Reference Laboratory-Antimicrobial Resistance recommended screening guidance (http://www.crl-ar.eu/201-resources.htm#cutoff). Temocillin and cefoxitin were included in the panel to aid detection of OXA-48-like carbapenemases and AmpC production, respectively.
Results
Epidemiological analysis and typing data
Of the 155 cases in this study, 76 (49.0%) were female, 70 (45.2%) were male and it was not possible to determine gender from the information provided for 9 cases. There were 105 (67.7%) adults (.16 years old), 43 (27.7%) children (16 years old) and the date of birth was not provided for 7 cases. A travel history was provided for 96 of 155 (61.9%) cases, of which 83 of 155 (53.5%) reported travel within 7 days of onset of symptoms and 13 (8.4%) reporting no travel in that time frame. No travel history was provided by 59 (38.1%) cases. The top five travel destinations reported were India (n " 20), Pakistan (n " 8), Egypt (n " 6), Turkey (n " 6) and Morocco (n " 4) ( Table S1 ).
The five most common STs were ST200 (n " 20), ST10 (n " 14), ST34 (n " 13), ST678 (n " 9) and ST38 (n " 8). The five most common serotypes were O92:H33 (n " 12), O126:H27 (n " 10), O175:H31 (n " 9), O55:H21 (n " 6) and O104:H4 (n " 6).
Comparison between phenotypic and genotypic AMR
Comparison of the phenotypic and genotypic AMR results showed 130 of 155 isolates (83.9%) having concordant results across their complete susceptibility profile, which included 10 classes of antimicrobials. There were 25 isolates that had one discrepant result making a total of 25 discordant results of 1550 isolate/antimicrobial combinations (1.6%). Of these, 24 were major errors, where isolates were predicted to be resistant from the genome-derived AMR data, but were phenotypically susceptible to the corresponding antimicrobial, and one was a very major error, with isolates predicted to be susceptible from the genome-derived AMR data, but phenotypically resistant to the corresponding antimicrobial ( Table 1) .
The major errors consisted of: 1 isolate with bla CTX-M-15 but phenotypically susceptible to cefotaxime and ceftazidime (MIC ,0.25 mg/L); 14 isolates were predicted resistant to streptomycin; 8 were predicted resistant to sulphonamides; and 1 was predicted resistant to chloramphenicol. All were phenotypically susceptible to the corresponding antimicrobials ( Table 1 ). The corresponding MICs were streptomycin 1-4 mg/L, sulphonamides 8-32 mg/L and chloramphenicol ,8 mg/L.
The eight samples that were phenotypically susceptible to sulphonamides despite carrying sul1 had the same combination of bla DHA-1 , dfrA17, qnrB4 and sul1 resistance determinants. Sequence analysis of the genetic environment of the sulphonamide resistance determinant using de novo assembled genomes showed that the promoter sequences were non-functional in all eight isolates due to the insertion of an ethidium bromide resistance gene upstream of the start codon of sul1. Fourteen other isolates were phenotypically susceptible to streptomycin but carried either an aadA variant (n " 9) or the strA-strB operon (n " 5). Of the five harbouring strA-strB, three had the operon located in an integron type I mobile element in which the strA gene was functionally inactivated by insertion of the dfrA14 cassette in the coding sequence of strA-strB. The fourth isolate had a truncated strA gene, whereas the remaining isolate carried intact strA-strB genes and explanation for the mismatch could not be identified from the WGS data. All the remaining nine isolates carried intact aadA genes that were co-located in integrons with dfrA variants responsible for WGS prediction of resistance in enteroaggregative Escherichia coli JAC trimethoprim resistance. Sequence analysis identified high sequence identity to previously described aadA5-dfrA17 (n " 3), dfrA12-aadA2 (n " 2) and dfrA1-aadA1b (n " 4) integrons. Previous studies showed that isolates expressing these adenylyltransferases were associated with lower MICs of streptomycin (MIC of ,16 mg/L) when compared with other variants. 18 No explanation for the discordant results was identified in the genome for the two isolates harbouring bla CTX-M-15 or catA1 but exhibiting no corresponding phenotypic resistance to cefotaxime/ ceftazidime or chloramphenicol.
The isolate yielding a very major error, predicted to be susceptible from the genome-derived AMR data (i.e. no resistance genes found), was phenotypically resistant to streptomycin (MIC .32 mg/L).
Resistance to b-lactams
Of the 155 isolates in this study, 87 (56.1%) had genes predicted to confer resistance to ampicillin (Tables 1 and 2) . Specifically, the genes detected encoded the penicillinases bla TEM-1 (n " 63) and bla OXA-1 (n " 9) or the ESBLs bla CTX-M-15 (n " 29) and bla CTX-M-14 (n " 2) ( Table 2) . Twenty-two isolates with bla TEM-1 or bla OXA-1 also had a CTX-M variant (bla CTX-M-15 , n " 20; bla CTX-M-14 , n " 2) ( Table 3) . Acquired ampC genes were detected in 10 isolates (bla DHA-1 , n " 9; bla CMY-16 , n " 1). Eight of the isolates with bla DHA-1 belonged to the same ST (ST200) and serotype (O175:H31), but were not epidemiologically linked. One isolate from a patient who had recently returned to the UK from Pakistan (within 7 days of onset of symptoms) had the carbapenemase OXA-181, in addition to 12 acquired genetic resistance determinants, one mutation in gyrA and two mutations in parC (Table 3) .
Resistance to quinolones
Resistances to ciprofloxacin (MICs .0.5 mg/L) and nalidixic acid were detected in 18 (11.6%) isolates, of which 9 had three mutations in gyrA and parC, 4 had four mutations and in 1 isolate five mutations were detected (Tables 3 and 4 (Table 4) .
Fifty-six isolates exhibited reduced susceptibility (MICs 0.125-0.25 mg/L) to ciprofloxacin (n " 10), resistance to nalidixic acid (n " 22) or both (n " 24) (Table 4 ). Of the 24 that had reduced susceptibility to ciprofloxacin and were resistant to nalidixic acid, 5 had a single mutation in each of gyrA and parC (1 isolate also had qnrB4), 17 had a single mutation in gyrA and 2 had a single mutation in gyrA and harboured qnrS1. Twenty-two isolates were resistant to nalidixic acid but fully susceptible to ciprofloxacin and all had single mutations in gyrA. PMQR determinants were detected in 23 isolates (Table 2 ), of which 13 had PMQR determinants and no mutations in gyrA or parC. Nine (qnrS1, n " 3; qnrB4, n " 3; qnrB19, n " 3) of these 13 isolates exhibited reduced susceptibility to ciprofloxacin (MICs 0.125-0.25 mg/L) and were susceptible to nalidixic acid, and 4 (qnrB4, n " 4) were fully susceptible to both ciprofloxacin and nalidixic acid.
Resistance to aminoglycosides
Sixty-two (40.0%) isolates had genes expected to confer streptomycin resistance. Fifty had strA-strB, of which 36 had strA-strB only. Five isolates had aac(6 0 )-Ib-cr with or without strA-strB or aadA variants, conferring resistance to tobramycin (Tables 2 and 3 ). Do Nascimento et al.
aac(6 0 )-Ib-cr also confers reduced susceptibility or resistance to ciprofloxacin. 19 All six isolates harbouring aac(6 0 )-Ib-cr were resistant to ciprofloxacin, but also had mutations in gyrA and parC. Five isolates had aac(3)-IIa (n " 4) or ant(2 00 )-Ia (n " 1), and strA-strB with or without additional aac or aad variants, conferring resistance to a broad range of aminoglycosides, including gentamicin and tobramycin (Table 2 and Table S1 ). No 16S rRNA methyltransferase genes were detected.
Resistance to sulphonamides, trimethoprim and tetracyclines
Seventy-five (48.4%) isolates had one or more dfrA genes (dfrA1, n " 25; dfrA5, n " 5; dfrA7, n " 13; dfrA8, n " 7; dfrA12, n " 4; dfrA14, n " 9; dfrA17, n " 16; dfrA18, n " 1), conferring resistance to trimethoprim (Table 2 ). There were five isolates with two different dfrA genes (dfrA1-dfrA17, n " 2; dfrA1-dfrA5, n " 1; dfrA7-dfrA14, n " 1; dfrA8-dfrA17, n " 1).
Fifty-five (35.5%) isolates had either tet(A) (n " 49) or tet(D) (n " 6) ( Table 2) ; no other tetracycline resistance determinants were detected.
Seventy-seven (49.7%) isolates had genes expected to confer sulphonamide resistance; 19 had sul1, 44 had sul2 and 14 had both sul1 and sul2 (Table 2 and Table S1 ).
Resistance to phenicols and macrolides
Fifteen isolates (9.7%) had catA1, predicted to confer chloramphenicol resistance (Table 2) . Genes predicted to be associated with macrolide resistance were found in 28 (18.1%) isolates; 5 had both erm(B) and mph(A), and 23 had mph(A) only.
Resistance to rifamycins, fosfomycin and colistin
None of the isolates was predicted to be resistant to the rifamycins or fosfomycin and no acquired genes associated with colistin resistance were detected.
MDR AMR profiles
Based on the WGS prediction, 112 (72.3%) of 155 isolates were resistant to at least one antimicrobial on the panel tested and 88 (56.8%) were MDR (resistant to three or more classes of antimicrobials) (Table 3) . 20 There were no common resistance determinant profiles in this dataset. The highest number of isolates that shared the same genotypic resistance determinant profiles was five, gyrA[83:S-A] and bla DHA-1 /qnrB4/mph(A)/dfrA17/sul1 (Table 3) .
Discussion
A growing number of studies have shown a good correlation between phenotypic and genotypic AMR profiles, and this study provides further evidence of a high level of concordance (98.4%) between the two approaches while also extending the pathogens considered to include EAEC. [21] [22] [23] In this study, the majority of mismatches (24 of 25) were isolates that were predicted to be genotypically resistant to a specific antimicrobial from the genome-derived data but that were found phenotypically susceptible to relevant antimicrobials, indicating that the AMR determinants were present but not expressed or expressed poorly. Silent resistant genes have been described previously. 24 There were nine isolates that had aadA variants predicted to confer resistance to streptomycin but that were reported as 'WT' (16 mg/L) phenotypically. 25 It has been shown previously that aadA variants are often found in integrons and the further away 
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Continued WGS prediction of resistance in enteroaggregative Escherichia coli JAC the aadA gene cassette is from the promoter the lower the expression. 26, 27 Moran et al. 28 recently showed that in isolates where the copy number was low, aadA5 downstream of dfrA17 did not confer phenotypic streptomycin resistance. Zankari et al. 22 suggested that differences in susceptibility to the aminoglycosides were related to the class of integrons with which the aadA variants were associated. Gestal et al. 29 describe a novel cassette array, dfrA12-orfF-aadA8b, created by a recombination event occurring within the aadA2 cassette in the dfrA12-orfF-aadA2 array, but did not comment on whether this event results in lack of expression.
In four of the five isolates harbouring strA-strB that were phenotypically susceptible to streptomycin (16 mg/L), the genetic determinant was rendered non-functional by an insertion or truncated. In the fifth isolate the strA-strB determinant was intact. Tyson et al. 23 also reported that the majority of discordant results in their study were associated with streptomycin and were attributable to the inability to detect evidence of phenotypic resistance, despite the isolates having intact coding regions and promoters. We previously reported isolates of Shigella sonnei harbouring strAstrB that were phenotypically susceptible to streptomycin, where the MICs were just below the breakpoint used during that study (8 mg/L). 16 Tyson et al. 23 argued that although a reduction in the MIC cut-off may result in better genotype-phenotype correlation, optimized streptomycin breakpoints can still result in substantial discrepancies with genotypic data. They proposed the presence of these genes should be used as an indicator of resistance potential and this may present a reasonable alternative to conventional phenotypic testing. 23 A dysfunctional promoter appeared to be responsible for the low levels of expression of sul1 in the eight isolates predicted to be resistant to the sulphonamides but phenotypically susceptible.
For the isolate that was phenotypically resistant to streptomycin with no corresponding AMR determinant, the MIC was .32 mg/L, significantly higher than the expected value for WT isolates. Although every effort is made in the laboratory to identify cultures containing more than one organism with the use of selective and/or chromogenic media, contamination of the culture during storage cannot be ruled out. The presence of efflux mechanisms and/or novel resistance mechanisms, that have not been previously identified, are alternative possibilities.
MDR appears to be common in EAEC and geographically widespread. Isolates of EAEC exhibiting high incidence of resistance to co-trimoxazole, ampicillin and tetracyclines were detected in studies carried out in Africa and Asia. 9, 12 In studies in Central and South America from 2006 to 2007, the most common E. coli pathogens in cases of diarrhoea were EAEC (14%), of which .90% of isolates were resistant to ampicillin, trimethoprim, tetracycline or nalidixic acid. 10 During a study in India between 2006 and 2007, an increase in EAEC isolates with resistance to quinolones was observed. 30 In Europe, of 160 strains of E. coli identified as EAEC isolated from patients in England with infectious intestinal disease or gastroenteritis between 1993 and 1996, .50% were resistant to one or more of eight antimicrobials, and 30 (19%) were resistant to four or more drugs with one strain being resistant to eight antimicrobials. 7 MDR isolates of EAEC have been described elsewhere in Europe, notably in Poland and Spain. 11, 31 The occurrence of AMR in EAEC is high compared with other E. coli pathotypes associated with food-production animals, specifically Shiga toxin-producing E. coli (STEC). Although AMR has Do Nascimento et al.
been identified in STEC from both human infections 13 and from cattle and beef products, 32 resistance appears to be less common than in EAEC isolates from cases of human infection. Possible explanations for this anomaly may be either differences in the innate propensity of STEC and EAEC strains to acquire and maintain plasmids encoding AMR determinants, or to antimicrobial selective pressure, with human cases with EAEC infections more likely to be exposed to antimicrobials than cattle, the major reservoir of STEC.
An alternative explanation for the high levels of AMR found in EAEC is the association with travellers' diarrhoea. Travel history is poorly captured on laboratory submission forms by general practitioners in England. Despite this, 53.5% of cases in this study reported travel abroad ,7 days before onset of symptoms. Resistance to ampicillin, cefotaxime (encoded by a CTX-M-15 b-lactamase), gentamicin, co-trimoxazole, nalidixic acid and ciprofloxacin has been reported in EAEC isolates from travellers from India returning to Spain. 33, 34 The most frequently used first-line antimicrobials for the treatment of travellers' diarrhoea are ampicillin, co-trimoxazole, tetracyclines (doxycycline) and quinolones, due to their ready availability and inexpensive cost. 33 The emergence of MDR strains often coupled with resistance to quinolones and thirdgeneration cephalosporins has compromised treatment. 35 Currently, published evidence does not support use of WGSinferred AMR profiles to guide clinical decision making, but WGS could replace phenotypic testing for surveillance purposes. 36 Despite the known limitations to the WGS approach, studies comparing phenotypic and genome-derived AMR profiles continue to show good correlation between the two methods, and to shed light on the reasons for observed discrepant results. [19] [20] [21] These data are prompting support for the use of this approach to provide options for patients' treatment. Genome-derived AMR profiles rapidly delivered to the patient's bedside provide a high-quality, comprehensive and robust evidence base for treatment, particularly for infections caused by pathogens that are very slow growing or difficult to culture (http://www.phgfoundation.org/documents/ 409_1416490432.pdf). With respect to the small number of discordant phenotypic and genome-derived AMR profiles, a better understanding of the role of allelic variants, specific gene combinations and promoter/attenuator mechanisms in the phenotypic 
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